PWS
GMAB icon

Paragon Wealth Strategies’s Genmab GMAB Stock Holding History

Paragon Wealth Strategies’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-640
Closed -$27.1K – 110
2022
Q4 		$27.1K Hold
640
– – 0.03% 88
2022
Q3 		$21K Buy
+640
New +$22.5K 0.02% 73
2021
Q3 		– Sell
-640
Closed -$26K – 136
2021
Q2 		$26K Buy
+640
New +$24.7K 0.01% 117

Other funds holding GMAB

AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
1832 Asset Management
1832 Asset Management Toronto, Ontario, Canada $109B AUM 35.56% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return

Paragon Wealth Strategies's GMAB Position: Q1 2023 in Review

Paragon Wealth Strategies sold out of Genmab (GMAB) in Q1 2023, closing a stake of 640 shares — an estimated $27.1K sold.

Paragon Wealth Strategies first reported a position in GMAB in Q2 2021 and held it in 3 quarters. The position peaked at $27.1K in Q4 2022. 216 funds tracked by Wall St. Rank hold GMAB as of Q1 2023.

  • Paragon Wealth Strategies reported no remaining Genmab position as of Q1 2023 after selling out during the quarter.
  • Paragon Wealth Strategies sold 640 Genmab shares in Q1 2023, an estimated $27.1K.
  • Paragon Wealth Strategies first reported a position in Genmab in Q2 2021 and held it in 3 quarters.
  • Paragon Wealth Strategies's Genmab position peaked at $27.1K in Q4 2022.
  • 216 funds tracked by Wall St. Rank held Genmab as of Q1 2023.

Based on Paragon Wealth Strategies's 13F filing for Q1 2023, filed 26 Apr 2023.